Royal Bank of Canada reiterated their outperform rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a report issued on Wednesday morning,Benzinga reports. Royal Bank of Canada currently has a $310.00 target price on the biopharmaceutical company’s stock. ALNY has been the topic of a number of other research reports. William Blair reissued […]

JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals (NASDAQ:AMRX – Free Report) from a neutral rating to an overweight rating in a report issued on Monday, MarketBeat Ratings reports. They currently have $12.00 target price on the stock, up from their prior target price of $9.00. Several other equities research analysts also recently issued […]